Mark Christianson
About Mark Christianson
Mark Christianson is a co-founder of NeuroOne Medical Technologies Corporation and has served as Business Development Director and Medical Sales Liaison since February 2019; he is 57 and studied accounting at Augsburg College in Minneapolis . Company performance during his tenure has shown product revenue growth of 77% in FY 2024 to $3.45M, alongside a net loss of $12.32M and product gross margin of 31.3% . Management has guided FY 2025 product revenue to $8–10M and gross margins to 50–53%, supported by an expanded Zimmer Biomet distribution agreement with a $3.0M upfront payment . The company’s proxy discloses Pay-vs-Performance metrics including TSR values for 2022–2024, providing context for shareholder outcomes .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| NeuroOne Medical Technologies Corp. | Business Development Director & Medical Sales Liaison | Feb 2019–present | Co-founder; contributed to development and corporate strategy; leveraged epilepsy KOL relationships |
| NeuroOne Medical Technologies Corp. | VP, Business Development & Marketing | Jul 2017–Feb 2019 | Led business development and marketing prior to current role |
| NeuroOne, Inc. (subsidiary) | VP of Sales & Marketing | Dec 2016–(role transitioned by Feb 2019) | Built sales/marketing capability for subsidiary |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Cortec Corporation | North American Sales Manager | May 2013–Dec 2016 | Commercial leadership in industrial products sales |
| Robert Half International (NYSE: RHI) | Business Development Executive | Feb 2012–May 2013 | Business development experience in professional services |
| PMT Corporation | Regional Sales Manager | May 2009–Feb 2012 | Regional sales management in medtech |
Fixed Compensation
- Christianson is listed as an executive officer but was not a named executive officer (NEO) in FY 2024; therefore, current base salary, target bonus, and stock/option grant disclosures for him do not appear in the Summary Compensation Table .
- Historical total compensation (2016–2018) for Christianson was disclosed via an 8-K update; see Performance Compensation table below .
Performance Compensation
- Company NEO annual incentive framework (context): For FY 2024, weighted performance targets across R&D, financing, commercialization milestones, and other corporate goals were set; payouts were approved at 85% of target for NEOs (CEO 50% target; COO 40%; CFO 25%) .
- Representative vesting schedules used in FY 2024 awards (context): RSUs often structured to vest 50% at first anniversary with remaining shares vesting monthly or quarterly thereafter; some RSUs vest 25% annually over four years . Options granted to senior executives have 25% cliff vest at year one then monthly vesting over 36 months .
Multi-year compensation (historical, 2016–2018):
| Metric | 2016 | 2017 | 2018 (Transition Period) |
|---|---|---|---|
| Non-Equity Incentive Plan Compensation ($) | $0 | $37,500 | $36,675 |
| Total Compensation ($) | $17,497 | $246,508 | $194,175 |
Performance metrics context (company-level, during Christianson’s tenure):
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Product Revenue ($) | $1,952,441 | $3,453,003 |
| Product Gross Profit ($) | $456,517 | $1,079,667 |
| Product Gross Margin (%) | 23.4% | 31.3% |
| Net Loss ($) | $11,859,491 | $12,318,110 |
Pay-vs-Performance TSR (proxy disclosure):
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Total Shareholder Return ($) | $42.25 | $22.25 | $24.75 |
Equity Ownership & Alignment
- Beneficial ownership table in the 2025 proxy covers directors and NEOs; Christianson is not included, so current beneficial ownership figures for him are not disclosed there .
- Insider trading and hedging policy: Company prohibits hedging (short sales, puts/calls, collars, swaps, monetization) and mandates pre-clearance and trading windows; blackout period runs from last trading day of fiscal quarter through two full trading days after earnings or filings .
- Pledging: Company prohibits officers and directors from pledging company securities or holding them in margin accounts .
- Clawback: Nasdaq-compliant policy requires recovery of erroneously awarded incentive-based compensation from Section 16 officers for three full years preceding an accounting restatement, regardless of fault .
- Insider selling: One late Form 4 filing reported the sale of 2,189 shares on June 6, 2024 (filed June 11, 2024) .
Insider transaction detail:
| Trade Date | Shares | Filing Note |
|---|---|---|
| 2024-06-06 | 2,189 | Form 4 filed late on 2024-06-11 |
Employment Terms
- Role and tenure: Co-founder; Business Development Director & Medical Sales Liaison since February 2019 .
- Contract terms (salary/bonus/severance): Not disclosed for Christianson in recent proxy/filings; he is not a named executive officer in FY 2024 disclosures .
- Company-wide governance context relevant to executives: Compensation Committee composed of independent directors (Buckman—Chair, Andrle, Mathiesen) with Grant Thornton as independent advisor for FY 2024 . Insider Trading Compliance Policy requires pre-clearance and prohibits hedging/pledging . Clawback policy applies to Section 16 officers .
Investment Implications
- Alignment: As co-founder with ongoing commercial responsibilities, Christianson’s alignment is supported by company-wide prohibitions on hedging/pledging and the application of the clawback policy to Section 16 officers . Lack of current beneficial ownership disclosure in the proxy for non-NEO executives limits visibility into his skin-in-the-game .
- Selling pressure: Documented sale of 2,189 shares in June 2024 suggests limited recent selling activity; no pledging is permitted, reducing forced-sale risk via collateral calls .
- Pay-for-performance transparency: Christianson’s current fixed and incentive compensation are not disclosed in FY 2024/2025 proxy tables, constraining direct assessment of his pay linkage to performance; historical (2016–2018) cash bonus and total pay were modest relative to current NEO disclosures .
- Execution risk and value creation context: Company revenue growth and margin trajectory, plus Zimmer Biomet agreement and FY 2025 guidance, indicate improving commercial traction; these are relevant context for evaluating Christianson’s business development impact, though no filing explicitly attributes specific milestones to him .